Ozempic vs. Semaglutide: Is the Cheaper Version Actually Legal?

Is 'semaglutide' without a brand name just cheaper Ozempic, or something different?

Both contain the exact same active ingredient: semaglutide, a GLP-1 receptor agonist. That's the part the ads aren't lying about. What differs is everything around the molecule. Ozempic is a specific, trademarked finished product — a fixed formulation, in Novo Nordisk's pen or tablet, manufactured under FDA oversight that checks potency, sterility, and consistency from batch to batch. The cheaper version being marketed as 'semaglutide' (rarely, and usually incorrectly, as 'compounded Ozempic') is prepared by a licensed 503A compounding pharmacy, mixed to a prescription for one named patient rather than manufactured as a mass-market drug.

That distinction isn't a technicality. No compounding pharmacy has legal standing to copy Novo Nordisk's finished, trademarked product — a provider advertising 'compounded Ozempic' as a product name is misusing a trademark, not describing a real category. What a 503A pharmacy can legally do is compound the underlying molecule, semaglutide, under its own generic name, and only under conditions that have gotten considerably narrower since 2024. Those conditions are the actual load-bearing question here, not the price tag, and they're covered next.

Is compounded semaglutide even legal right now — the 2026 FDA rules

Yes, but through a door that's gotten a lot narrower than it was during the 2022-2024 shortage. The FDA declared the national semaglutide shortage resolved in February 2025. Enforcement discretion that had let compounding pharmacies fill semaglutide broadly ended for 503A pharmacies on April 22, 2025, and for larger-scale 503B outsourcing facilities a month later. Compounders challenged that delisting decision in court, and on August 27, 2026 — about three weeks before this was last checked — the Fifth Circuit Court of Appeals affirmed the FDA's removal of semaglutide from the shortage list as lawful. As of this writing, no rehearing or Supreme Court petition has been filed against that ruling, but it's recent enough that the legal picture is worth re-checking before you rely on it.

What survives is a narrower individual-patient pathway. In an April 2026 policy clarification, the FDA confirmed that a 503A pharmacy can still compound semaglutide that is 'essentially a copy' of a commercial product — but only when the prescribing clinician determines and documents, for that one specific patient, that the compounded version produces a clinically significant difference the commercial drug doesn't. Wanting a lower price isn't, on its own, a qualifying reason under that standard, and the FDA explicitly said the determination can't be boilerplate language copied across a patient list — it has to be individualized. There's also a low-volume safe harbor: the FDA said it won't pursue a pharmacy filling four or fewer prescriptions of a given formulation in a calendar month. That threshold is tiny relative to what a national telehealth brand serves, which is why legitimate large-scale providers lean on the documented clinical-difference standard rather than volume limits to stay compliant.

The FDA has also been actively enforcing this line. It issued warning letters to more than 50 telehealth and compounding sellers in September 2025, and another wave to roughly 30 companies in March 2026, over marketing that overstated how personalized or equivalent their products were. Separately, Novo Nordisk has filed well over a hundred lawsuits against compounders and telehealth sellers for using its trademarks or overstating equivalence, winning a permanent injunction against one compounder in 2025 and filing a further patent suit against a telehealth provider in early 2026. None of that makes compounded semaglutide itself illegal — it means the market has been actively narrowed to providers who can document the individual-patient exception, and a meaningful number of sellers who couldn't have already been pushed out or warned.

What's the real price difference, with and without insurance

If you have commercial insurance and a type 2 diabetes diagnosis, brand Ozempic wins outright. The NovoCare savings card brings a covered copay down to roughly $25 to $50 a month — about $300 to $600 a year — which beats every compounded option on this page. Government insurance (Medicare, Medicaid, TRICARE) is excluded from that card entirely.

Without insurance, the gap widens. Novo Nordisk's self-pay program runs $199 a month for the first two fills at starter doses, then settles at $349 a month for doses up to 1mg or $499 a month for the 2mg pen — roughly $4,188 to $5,988 a year at maintenance. Skip any savings program entirely and Ozempic's retail cash price runs $1,028 to $1,100 a month, or somewhere around $12,300 to $13,200 a year, depending on the pharmacy.

Compounded semaglutide, by contrast, runs roughly $150 to $300 a month across the providers still operating under the individual-patient exception — about $1,800 to $3,564 a year. That's a potential savings of $2,000 to $10,000 a year against brand Ozempic without insurance, which is the entire reason this comparison exists for so many women. It's also, per the section above, a savings that comes with a narrower and more scrutinized legal basis than it did two years ago.

Is compounded semaglutide safe — dosing accuracy and quality control vs. an FDA-approved pen

Same active molecule, different oversight. The FDA reviews Ozempic's manufacturing process, sterility, and dose-to-dose consistency as a condition of approval. It doesn't review a compounded formulation the same way — that's the practical meaning of 'not FDA-approved as a finished product.' Nobody outside the compounding pharmacy itself has independently verified that your vial matches the last one, or the next one.

That doesn't automatically make compounded semaglutide unsafe. State-licensed 503A pharmacies operate under state pharmacy board oversight and the federal Drug Quality and Security Act, and reputable telehealth providers work with named, checkable pharmacy partners. But it does mean the specific compounding pharmacy behind your prescription — not just the brand name on the telehealth website — is the thing worth actually asking about. Some compounded formulations also add ingredients Ozempic doesn't contain, most often B12 or an amino acid blend marketed for energy, that haven't been independently evaluated in combination with semaglutide.

Does compounded semaglutide work as well as Ozempic?

For the molecule itself, there's no biological reason it would behave differently — semaglutide is semaglutide, and its effect on appetite and blood sugar comes from the active compound, not the brand name on the box. Where compounded products can genuinely diverge from a pen is in the details that come with compounding: concentration per milliliter, buffer and preservative formulation, and how consistently a given pharmacy hits its target potency batch to batch. A reputable 503A pharmacy with real quality controls should produce a formulation that performs the same as the branded product for most patients. The FDA's concern isn't that the chemistry is different — it's that, unlike Ozempic, nobody is independently confirming that consistency for you.

Which providers still legitimately offer compounded semaglutide, and at what price

The providers below have stayed inside the narrowed 503A individual-patient pathway rather than the broad, shortage-era compounding that's now closed. This isn't the exhaustive list — for the full provider-by-provider rundown, see compounded semaglutide — but these three are the ones we've most consistently been able to verify with a real, all-in monthly price.

Henry Meds — flat price, no membership fee

Henry Meds bundles the medication, provider visits, supplies, and shipping into one monthly number that doesn't climb as your dose increases: $249/mo for the oral option, $297/mo for the weekly injectable. No separate membership sits on top. The company works through a network of 503A pharmacies and, as of this writing, has not received an FDA warning letter — though it is a named defendant in an Eli Lilly lawsuit over marketing language for a related tirzepatide product, a case that's ongoing on a narrow claim.

Mochi Health — the lowest all-in price here

Mochi splits its pricing into a $99/mo medication fee and a roughly $79/mo membership, for about $178/mo all-in — the cheapest of the three once both lines are added together. The medication price stays flat regardless of dose, and the platform requires its physician network to hold ABOM (obesity medicine) board certification, a genuine differentiator in this category.

Fridays — cheapest with an annual commitment

Fridays bundles dietitian access and group coaching into its price and rewards a full-year commitment: about $150/mo on the annual plan, versus roughly $249/mo month-to-month. The annual rate is the lowest verified price on this page, but it's a prepaid, largely non-refundable commitment — worth weighing against the flexibility of a month-to-month option if your circumstances (or the regulatory landscape) might change within the year.

When brand Ozempic actually ends up cheaper than 'cheap' semaglutide

The math flips entirely for one group: commercially insured patients with a type 2 diabetes diagnosis. The NovoCare savings card's $25-to-$50 range beats every compounded price on this page, often by a wide margin, and it comes with the FDA's full manufacturing oversight attached. If that describes you, there's rarely a reason to look at compounded semaglutide at all — Ozempic cost walks through every insured and self-pay pathway in more detail.

There's also a forward-looking wrinkle worth knowing about. Novo Nordisk announced in February 2026 that it will move Ozempic to a single, flat list price of roughly $675 a month across all doses, effective January 1, 2027 — a cut of about a third from today's list price. That change targets list price specifically, and self-pay and cash pricing may not track it dollar for dollar, but it's a meaningful signal that the gap between brand Ozempic and compounded semaglutide is likely to narrow further next year, not widen. If your timeline allows it, that's worth factoring into a decision to lock into a compounded provider's annual plan today.

Switching between Ozempic and a compounded version without disrupting titration

Semaglutide is semaglutide, but the products delivering it aren't always interchangeable milliliter for milliliter. A compounded formulation's concentration per dose can differ from Ozempic's pen, and pen 'click' doses don't automatically translate to a compounded syringe's markings. Whichever direction you're switching — brand to compounded, or compounded back to brand, which happens if a provider exits the market — have your new prescriber recalculate and confirm your specific dose in writing before your first fill, rather than assuming your old regimen carries over exactly. Keep your current pen or vial until the new prescription is confirmed, so you don't have a gap in supply while the switch is arranged.

Red flags: how to spot an illegitimate compounder or gray-market seller

• Markets the product as 'compounded Ozempic' by name, rather than clearly saying 'compounded semaglutide' — a sign of either sloppy marketing or a trademark problem worth avoiding.
• Won't name the 503A pharmacy filling your prescription, or dodges the question when you ask directly.
• No real clinical consultation before checkout — just a form and a shipment, with no clinician reviewing your history.
• A price meaningfully below everything on this page, with no explanation for how that's possible.
• Sells 'research chemical' or unlabeled vials with no prescription requirement at all — this is not a legal patient pathway under any interpretation of current FDA rules.